25 May 2013
Keywords: crucell, signs, cross-licensing, deal, merck, co, dutch
Article | 08 January 2007
Dutch biotechnology company Crucell NV has signed a cross-licensing agreement with US drug major Merck & Co. In addition to
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 January 2007
24 May 2013
© 2013 thepharmaletter.com